144 related articles for article (PubMed ID: 529054)
1. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold A; McAuliff MP; Beyler AL
J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
[TBL] [Abstract][Full Text] [Related]
2. The effect of ciprofibrate on gastric secretion in the rat.
Eason CT; Pattison A; Howells DD; Bonner FW
J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
[TBL] [Abstract][Full Text] [Related]
3. Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.
Feller DR; Singh Y; Shirhatti VR; Kocarek TA; Liu CT; Krishna G
Hepatology; 1987; 7(3):508-16. PubMed ID: 3570161
[TBL] [Abstract][Full Text] [Related]
4. Hypolipemic activity of plafibride.
Bruseghini L; Vilageliu J; Bagaria A
Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
[TBL] [Abstract][Full Text] [Related]
5. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
[TBL] [Abstract][Full Text] [Related]
6. Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
Srinivasan SR; Chow CK; Glauert HP
Toxicology; 1990 Jun; 62(3):321-32. PubMed ID: 2389247
[TBL] [Abstract][Full Text] [Related]
7. The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
Arnold A; McAuliff JP; Powers LG; Phillips DK; Beyler AL
Atherosclerosis; 1979 Feb; 32(2):155-63. PubMed ID: 454514
[TBL] [Abstract][Full Text] [Related]
8. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
[TBL] [Abstract][Full Text] [Related]
9. [The action of a fibric acid derivative on lipid metabolism].
Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
Oelschläger H; Rothley D; Schmidt W
Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
[No Abstract] [Full Text] [Related]
11. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
Awasthi YC; Singh SV; Goel SK; Reddy JK
Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
[TBL] [Abstract][Full Text] [Related]
12. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
Simpson IA; Lorimer AR; Walker ID; Davidson JF
Thromb Haemost; 1985 Aug; 54(2):442-4. PubMed ID: 4082082
[TBL] [Abstract][Full Text] [Related]
13. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
Filip M; Hriscu A; Păduraru I; Rusu M
Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
[No Abstract] [Full Text] [Related]
14. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
[TBL] [Abstract][Full Text] [Related]
15. The effect of bezafibrate and clofibrate on microsomal ACAT and lysosomal cholesterol ester hydrolase activity in the cholesterol-fed rabbit aorta.
Hudson K; Day AJ
Atherosclerosis; 1982 Oct; 45(1):109-13. PubMed ID: 7159486
[TBL] [Abstract][Full Text] [Related]
16. Influence of a fibric acid type of hypolipidemic agent on the oxidative metabolism of arachidonic acid by liver microsomal cytochrome P-450.
Capdevila J; Kim YR; Martin-Wixtrom C; Falck JR; Manna S; Estabrook RW
Arch Biochem Biophys; 1985 Nov; 243(1):8-19. PubMed ID: 3933431
[TBL] [Abstract][Full Text] [Related]
17. Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.
Facino RM; Carini M
Pharmacol Res Commun; 1981 Oct; 13(9):861-71. PubMed ID: 7335763
[No Abstract] [Full Text] [Related]
18. An in vitro demonstration of peroxisome proliferation and increase in peroxisomal beta-oxidation system mRNAs in cultured rat hepatocytes treated with ciprofibrate.
Thangada S; Alvares K; Mangino M; Usman MI; Rao MS; Reddy JK
FEBS Lett; 1989 Jul; 250(2):205-10. PubMed ID: 2753129
[TBL] [Abstract][Full Text] [Related]
19. Induction and origin of hepatocytes in rat pancreas.
Reddy JK; Rao MS; Qureshi SA; Reddy MK; Scarpelli DG; Lalwani ND
J Cell Biol; 1984 Jun; 98(6):2082-90. PubMed ID: 6202703
[TBL] [Abstract][Full Text] [Related]
20. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
